acriflavine has been researched along with Urinary-Bladder-Neoplasms* in 1 studies
1 other study(ies) available for acriflavine and Urinary-Bladder-Neoplasms
| Article | Year |
|---|---|
Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy.
Resistance to cisplatin is a major obstacle to effective treatment of bladder cancer (BC). The present study aimed to determine whether a combination of acriflavine (ACF) with cisplatin could potentiate the antitumor property of cisplatin against the BC cells. Furthermore, the molecular mechanism behind the anticancer action of ACF was considered.. Two human BC cells (5637 and EJ138) contain mutated form of p53 was culture in standard condition. Cotreatment protocol (simultaneous combination of IC. Our findings indicate that combination of cisplatin with ACF was able to significantly enhance the sensitivity of BC cells to cisplatin. The antitumor activity of ACF is exerted through the downregulation of TOP1 and TOP2A genes expression. ACF may serve as an adjuvant to boost cisplatin-based chemotherapy. Topics: Acriflavine; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Humans; Urinary Bladder Neoplasms | 2022 |